Moderna rises, reaching highest price since March
Moderna is up more than 11% on seemingly no news beyond positive trial data for its experimental flu vaccine over a week ago.
The company, which still makes most of its revenue from declining COVID-19 vaccine sales, has been looking for a glimmer of hope as it learns to deal with an administration hostile to vaccines. The company is now up 20% since it announced the results last Monday, but is still down over 20% for the year.